A Turbo-Charging System-Like Contrast Agent for MRI-Guided STING Pathway-Activated Cancer Immunotherapy.

Adv Sci (Weinh) · 2025 · PMC11714149 · PMID 39488791

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

However, in the group III (SR717 dosage: 30 mg kg −1 ), a decreasing trend of the mouse weight is observed, indicating systemic toxicity of free SR717.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.